PENETRATION OF VP 16-213 INTO CEREBROSPINAL-FLUID AFTER HIGH-DOSE INTRAVENOUS ADMINISTRATION

被引：76

作者：

POSTMUS, PE

HOLTHUIS, JJM

HAAXMAREICHE, H

MULDER, NH

VENCKEN, LM

VANOORT, WJ

SLEIJFER, DT

SLUITER, HJ

机构：

[1] STATE UNIV GRONINGEN, DEPT PULM DIS, 9700 AB GRONINGEN, NETHERLANDS

[2] STATE UNIV GRONINGEN, DEPT NEUROL, 9700 AB GRONINGEN, NETHERLANDS

[3] STATE UNIV GRONINGEN, DEPT NEURORADIOL, 9700 AB GRONINGEN, NETHERLANDS

[4] STATE UNIV GRONINGEN, DEPT MED ONCOL, 9700 AB GRONINGEN, NETHERLANDS

[5] STATE UNIV UTRECHT, DEPT ANALYT PHARM, PHARMACEUT LAB, UTRECHT, NETHERLANDS

来源：

JOURNAL OF CLINICAL ONCOLOGY | 1984年 / 2卷 / 03期

关键词：

D O I：

10.1200/JCO.1984.2.3.215

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

VP 16-213 in standard doses is active against a number of solid tumors. Its penetration into the CSF is very limited at these dose levels. In 10 patients treated with high-dose VP 16-213 (0.9-2.5 g/m2), CSF levels of up to 0.54 .mu.g/ml were detected. In 2 patients with CNS metastases of small cell lung cancer (SCLC) a response was seen after 1.0 and 1.5 g/m2 i.v. High-dose VP 16-213 can possibly play a role in the treatment of CNS metastases of SCLC. Its application in late intensification regimens as a form of prophylaxis of CNS metastases should be investigated.

引用

页码：215 / 220

页数：6

共 20 条

[1] CARENESS WF, 1980, RAD DAMAGE NERVOUS S, P1
[2] CAVALLI F, 1978, CANCER TREAT REP, V62, P473
[3] COHEN MH, 1977, CANCER TREAT REP, V61, P489
[4] CREAVEN PJ, 1982, CANCER CHEMOTH PHARM, V7, P133
[5] EVANS WE, 1982, CANCER CHEMOTH PHARM, V7, P147
[6] GROOTHUIS D, CANCER TREAT REP
[7] Holthuis J J, 1983, J Pharm Biomed Anal, V1, P89, DOI 10.1016/0731-7085(83)80012-0
[8] ISSELL BF, 1982, CANCER CHEMOTH PHARM, V7, P73
[9] MAURER LH, 1980, CANCER-AM CANCER SOC, V45, P30, DOI 10.1002/1097-0142(19800101)45:1<30::AID-CNCR2820450107>3.0.CO
[10] 2-6

← 1 2 →